Unassociated Document Oramed's Dr. Roy Eldor was Chosen to Lecture at the First International Conference held by the Bildirici Center for Diabetes Care Research in Israel.

Dr. Roy Eldor was Chosen to Lecture at the First International

held by the Bildirici Center for Diabetes Care Research in Israel.

Israel - December 21, 2009- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB)

(http://www.oramed.com), a developer of alternative drug delivery systems,

announced today that Dr. Roy Eldor will present an overview of the clinical

development of Oramed's Oral Insulin capsule. Dr. Eldor is the

principal investigator for all of Oramed's clinical trials conducted at Hadassah

Medical Center. He is a physician in the Diabetes Unit and Endocrinology

Department of Hadassah Medical Center.

conference will take place at the Wohl Center, Bar Ilan University, in Ramat

Gan, Israel, on December 21-23. Dr. Eldor's presentation will be given on

December 22 at 4:10 PM. He will be highlighting all of the clinical work that

Oramed has completed to date, ranging from preclinical trials to its current

is honored to have been invited to present at this very important conference to

share the clinical development of its Oral Insulin Capsule with the scientific

community" says Dr. Roy Eldor.

Conference will start to focus on the translation of "cutting edge" diabetes

research into practical clinical care, with a particular emphasis on the

organization and delivery of care in different health systems. Updates and

overviews will be given by invited speakers from around the world, together with

workshop and debate sessions and submitted oral and poster

More information, please visit www.diabetescenter.org.il

Oramed Pharmaceuticals

Pharmaceuticals is a technology pioneer in the field of oral delivery solutions

for drugs and vaccines presently delivered via injection. Oramed is seeking

to revolutionize the treatment of diabetes through its patented flagship

product, an orally ingestible insulin capsule currently in phase 2 clinical

trials. Established in 2006, Oramed's technology is based on over 25 years of

research by top research scientists at Jerusalem's Hadassah Medical Center. The

Company's corporate and R&D headquarters are based in

information, please visit www.oramed.com.

Some of the statements contained in

this press release are forward-looking statements which involve known and

unknown risks, uncertainties and other factors which may cause the actual

results, performance or achievements of the company, or industry results, to be

materially different from any future results, performance or achievements

expressed or implied by such forward looking statements, including the risks and

uncertainties related to the progress, timing, cost, and results of clinical

trials and product development programs; difficulties or delays in obtaining

regulatory approval for our product candidates; competition from other

pharmaceutical or biotechnology companies; and the company's ability to obtain

additional funding required to conduct its research, development and

commercialization activities. Please refer to the company's filings with the

Securities and Exchange Commission for a comprehensive list of risk factors that

could cause actual results, performance or achievements of the company to differ

materially from those expressed or implied in such forward looking statements.

The company undertakes no obligation to update or revise any forward-looking

and Investor Relations Contacts:

Email: tara@oramed.com